NicholasRStraubeSSchmidliH. Time-patterns of annualized relapse rates in randomized placebo-controlled clinical trials in relapsing–remitting multiple sclerosis: A systematic review and meta-analysis. Mult Scler2012; 18: 1290–1296.
2.
UitdehaagBMBarkhofFCoylePK. The changing face of multiple sclerosis clinical trial populations. Curr Med Res Opin2011; 27: 1529–1537.
3.
AscherioAMungerKLWhiteR. Vitamin D as an early predictor of multiple sclerosis activity and progression. JAMA Neurol2014; 71: 306–314.
4.
DobsonRGiovannoniGRamagopalanS. The month of birth effect in multiple sclerosis: Systematic review, meta-analysis and effect of latitude. J Neurol Neurosurg Psychiatry2013; 84: 427–432.
5.
KellyMACavanDAPennyMA. The influence of HLA-DR and -DQ alleles on progression to multiple sclerosis following a clinically isolated syndrome. Hum Immunol1993; 37: 185–191.
CalabresiPAKieseierBCArnoldDL. Pegylated interferon β-1a for relapsing–remitting multiple sclerosis (ADVANCE): A randomised, phase 3, double-blind study. Lancet Neurol2014; 13: 657–665.
8.
KapposLRadueEWO’ConnorP. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med2010; 362: 387–401.
9.
O’ConnorPWolinskyJSConfavreuxC. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N Engl J Med2011; 365: 1293–1303.
10.
CohenJAColesAJArnoldDL. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing–remitting multiple sclerosis: A randomised controlled phase 3 trial. Lancet2012; 380: 1819–1828.
11.
ZivadinovRRederATFilippiM. Mechanisms of action of disease-modifying agents and brain volume changes in multiple sclerosis. Neurology2008; 71: 136–144.
